Beckman Coulter’s phi Named in NCCN Guidelines as a Recommended Diagnostic Test for Early Prostate Cancer Detection
2014 AACC Annual Meeting Press ProgramBeckman Coulter’s Prostate Health Index (phi)* has been recommended by the National Comprehensive Cancer Network (NCCN) as a blood test to improve specificity for prostate cancer detection in its recently updated Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer Early Detection. Inclusion in the NCCN Guidelines recognizes the benefit and clinical utility of phi for better prostate cancer diagnosis and for the reduction of unnecessary biopsies.